UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area
code (
not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 28, 2023, Edward Wholihan was appointed to the Board of Directors (the “Board”) of KORU Medical Systems, Inc. (the “Company”), filling the existing vacancy on the Board.
Mr. Wholihan has over 25 years of experience as a chief financial officer driving growth and shareholder value for public, private equity-sponsored, and venture capital-funded life sciences and healthcare businesses. Most recently, he has leveraged his strategic management, financial, and operational expertise consulting for various companies. Prior, he served as the Chief Financial Officer for Rarebreed Veterinary Partners, Inc., a community of veterinary hospitals; CFO of Allena Pharmaceuticals, Inc., a development stage biopharmaceutical company; and CFO of Medical Specialties Distributors, a leading solution provider to the specialty pharmacy, home infusion, and oncology practice markets. Mr. Wholihan also held two other CFO roles within the life science sector earlier in his career and, prior to that, spent seven years as a management strategy consultant for McKinsey & Company. He earned his MBA from Stanford University's Graduate School of Business and a BA in economics from Yale University.
Mr. Wholihan served as a consultant to the Company from January through June 2023, in exchange for which he received $131,250 in consulting fees. Mr. Wholihan will receive compensation as a non-employee director pursuant to the Company’s Non-Employee Director Compensation Plan.
Item 8.01. Other Events.
On October 4, 2023, the Company issued a press release announcing the events set forth in this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in Item 8.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished as part of this report:
Exhibit No. | Description |
99.1 | Press release dated October 4, 2023. |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KORU MEDICAL SYSTEMS, INC. (Registrant) | ||
Date: October 4, 2023 | By: | /s/ Thomas Adams |
Thomas Adams Chief Financial Officer |
- 3 -
EXHIBIT 99.1
KORU MEDICAL SYSTEMS, INC. ANNOUNCES APPOINTMENT OF EDWARD WHOLIHAN TO ITS BOARD OF DIRECTORS
MAHWAH, NJ – October 4, 2023 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company’s Board of Directors September 28, 2023 to fill the vacancy that followed the Company’s 2023 Annual Meeting of Shareholders.
“I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shareholder value in high-growth life science and healthcare businesses,” said Linda Tharby, KORU Medical’s President and CEO. “As we continue to build our leadership position in the subcutaneous infusion market with our FREEDOM Infusion System, Ed’s insights will meaningfully contribute to our future growth and success.”
Edward Wholihan joins KORU Medical’s Board of Directors with over 25 years of experience as Chief Financial Officer driving growth and shareholder value for public, private equity-sponsored, and venture capital-funded life sciences and healthcare businesses. Most recently, he has leveraged his strategic management, financial, and operational expertise consulting for various companies. Prior, he served as the Chief Financial Officer for Rarebreed Veterinary Partners, Inc, a community of veterinary hospitals; CFO of Allena Pharmaceuticals, Inc., a development stage biopharmaceutical company; and CFO of Medical Specialties Distributors, a leading solution provider to the specialty pharmacy, home infusion, and oncology practice markets that was acquired by McKesson Corp (NYSE:MCK) in 2018. Ed also held two other CFO roles within the life science sector earlier in his career and, prior to that, spent seven years as a management strategy consultant for McKinsey & Company. He earned his MBA from Stanford University’s Graduate School of Business and a BA in economics from Yale University.
“I am impressed with KORU Medical’s tremendous progress, innovation, and commitment toward growth, and I am excited to take part in helping the Company achieve its goal to improve the quality of life for patients around the world,” said Mr. Wholihan. “I look forward to supporting Linda and the KORU Medical team as they continue to drive the Company’s growth strategy and the provision of subcutaneous infusion therapies and their benefits to patients.”
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM™ Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
Investor Contact:
Greg Chodaczek
347-620-7010
investor@korumedical.com
Cover |
Sep. 28, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 28, 2023 |
Entity File Number | 0-12305 |
Entity Registrant Name | KORU MEDICAL SYSTEMS, INC. |
Entity Central Index Key | 0000704440 |
Entity Tax Identification Number | 13-3044880 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 100 Corporate Drive |
Entity Address, City or Town | Mahwah |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07430 |
City Area Code | 845 |
Local Phone Number | 469-2042 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | common stock, $0.01 par value |
Trading Symbol | KRMD |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
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end